» Articles » PMID: 10686371

Scopolamine Impairs Memory Performance and Reduces Frontal but Not Parietal Visual P3 Amplitude

Overview
Journal Biol Psychol
Specialty Psychiatry
Date 2000 Feb 25
PMID 10686371
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

It has been suggested that the P3 event-related potential (ERP) may mark the operation of certain working or long-term memory processes. It has also been reported that cholinergic blockade by scopolamine induces significant memory impairment and is associated with an increased latency, as well as amplitude reduction or abolition of the auditory P3, thus supporting hypothesised links between P3 and long-term memory function. An intriguing anomaly is that, while visual P3 latency is also increased by scopolamine, amplitude is not changed. The aim of this study was to make a more detailed assessment of the effects of scopolamine on the visual P3 at a drug dose known to induce memory impairment. After drug administration, memory performance was significantly impaired and visual P3 latency was significantly increased. There was little evidence of parietal P3 amplitude reduction, but frontal P3 amplitude was significantly reduced in both target and non-target conditions. These findings, when considered in the light of a more recent study of the effects of scopolamine on auditory P3, suggest that cholinergic blockade produces a common effect in both visual and auditory modalities of significant frontal P3 amplitude reduction, but no significant parietal P3 amplitude reduction. These results are consistent with the view that there are modality-independent generators of the parietal and frontal P3. The finding of drug-induced memory impairment and modulations of frontal ERP deflections is also consistent with recent evidence of a significant role for regions of the frontal lobe in encoding and retrieval of long-term memories.

Citing Articles

Cholinergic modulation of sensory perception and plasticity.

Kunnath A, Gifford R, Wallace M Neurosci Biobehav Rev. 2023; 152:105323.

PMID: 37467908 PMC: 10424559. DOI: 10.1016/j.neubiorev.2023.105323.


Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related Potential.

Olichney J, Xia J, Church K, Moebius H Neural Plast. 2022; 2022:2104880.

PMID: 36398135 PMC: 9666049. DOI: 10.1155/2022/2104880.


Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.

Hua X, Church K, Walker W, LHostis P, Viardot G, Danjou P J Alzheimers Dis. 2022; 86(3):1399-1413.

PMID: 35180125 PMC: 9108585. DOI: 10.3233/JAD-215511.


The motor vertical in the absence of gravicentric cues.

Bock O, Bury N NPJ Microgravity. 2020; 6:8.

PMID: 32195319 PMC: 7054271. DOI: 10.1038/s41526-020-0098-8.


Identification and pharmacological profile of SPP1, a potent, functionally selective and brain penetrant agonist at muscarinic M receptors.

Broad L, Sanger H, Mogg A, Colvin E, Zwart R, Evans D Br J Pharmacol. 2018; 176(1):110-126.

PMID: 30276808 PMC: 6284335. DOI: 10.1111/bph.14510.